American Society of Hematology

ASH Meeting on Hematologic Malignancies

September 7-8, 2018
Marriott Marquis Chicago, Chicago, IL


Visit ASH Academy to claim CME/MOC or request a certificate of attendance.

The ASH Meeting on Hematologic Malignancies features the top experts in the field, comprehensive clinical content, and the opportunity to interact with colleagues in an intimate, small-group setting with no competing sessions. Attend the 2018 meeting to hear experts present cutting-edge scientific data, provide outside-the-box treatment approaches, answer challenging patient care questions during topic-based panel discussions, and engage in stimulating conversations on specific disease topics during “Lunch With the Experts” sessions.

The program content is structured as "How I Treat" presentations, which showcase each speaker's evidence-based treatment approaches. Learn how new data can be translated into new strategies for diagnosis and treatment, find out what to do in cases where there is no data, and gain knowledge that can help you make an immediate impact on your practice.

Hear exciting updates in each of the core hematologic malignancies, including:

Program Co-Chairs

John P. Leonard, MD

John P. Leonard, MD
Weill Cornell Medical
College

S. Vincent Rajkumar, MD

S. Vincent Rajkumar, MD
Mayo Clinic

Gail Roboz, MD

Gail Roboz, MD
Weill Cornell Medical
College

Program Planning Committee

  • Anjali Advani, MD, Cleveland Clinic
  • Jonathan W. Friedberg, MD, University of Rochester
  • Irene Ghobrial, MD, Dana-Farber Cancer Institute
  • Ruben A. Mesa, MD, UT Health San Antonio Cancer Center

Exposition

ASH would like to acknowledge the following companies for exhibiting at the 2018 ASH Meeting on Hematologic Malignancies. Participants in this exposition are comprised of the most renowned companies in the industry, including:

  • Amgen, Inc.
  • AstraZeneca
  • Bayer HealthCare Pharmaceuticals
  • BMS/Pfizer
  • Celgene Corporation
  • Daiichi Sankyo
  • Genentech
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Kite Pharma
  • Merck & Co.
  • Novartis
  • Pfizer, Inc.
  • SOPHiA Genetics
  • Takeda Oncology
  • TG Therapeutics

For information about sponsoring and/or exhibiting at this meeting, contact Thelma Barnett at corporatesupport@hematology.org.

Corporate Support

ASH would like to acknowledge the following companies for the educational grants provided in support of the 2018 ASH Meeting on Hematologic Malignances.

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca
  • Astellas Pharma
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Jazz Pharmaceuticals
  • Merck & Co.
  • Novartis
  • Pfizer, Inc.
  • Pharmacyclics, An AbbVie Company
  • Takeda Oncology

Related Content

back to top